RELEASE: REdressing Long-tErm Antidepressant uSE in adults in general practice (RELEASE): A two-arm parallel-group cluster RCT effectiveness-implementation hybrid type-1 study
Authors:
- a pragmatic multicentre, superiority, parallel group, controlled study of participants allocated to a multi-strategy intervention vs Usual CareACa pragmatic multicentre, superiority, parallel group, controlled study of participants allocated to a multi-strategy intervention vs Usual Care
- Katharine WallisKWKatharine Wallis
- Maria DonaldMDMaria Donald
- Mark HorowitzMHMark Horowitz
- Rob WareRWRob Ware
- Joshua ByrnesJBJoshua Byrnes
- Joanna MoncrieffJMJoanna Moncrieff
- Nicholas ZwarNZNicholas Zwar
- Ian ScottISIan Scott
- Mark MorganMMMark Morgan
- Christopher FreemanCFChristopher Freeman
- Neeraj GillNGNeeraj Gill
Preprint
Abstract
The REdressing Long-tErm Antidepressant uSE in general practice (RELEASE) trial is a pragmatic cluster randomized controlled trial (cRCT) that seeks to determine whether a novel multi-strategy intervention that supports safe cessation of long-term antidepressants is superior to Usual Care. 1 Pragmatic trials are designed to determine how well interventions work in clinical practice under everyday conditions. 2 The multi-strategy intervention has two forms, known as RELEASE and RELEASE+. RELEASE for patients includes direct patient education and resources 3 and an invitation to medication review; RELEASE for general practitioners (GPs) includes education, training in the brief intervention (Ask, Advise, Assist) and printable resources via practice management software. RELEASE+ additionally includes for patients links to freely available information online via an App, and for GPs clinical audit and feedback on practice prescribing of antidepressants. Patient directed education material has the potential to support safer prescribing, including in this case improved recognition and management of antidepressant withdrawal symptoms. 4, 5 Brief interventions have the potential to change GP prescribing behaviour. 6 The primary comparison of interest is whether any RELEASE intervention is superior to Usual Care. A secondary comparison will be between the two types of RELEASE interventions (RELEASE and RELEASE+). The purpose of this document is to minimise bias and ensure transparency and internal validity for the findings of the trial, by defining and making publicly available the analysis approach prior to reviewing or analysing trial data. The statistical analysis plan (SAP) will inform analysis and reporting of the main effectiveness findings of the trial. It provides a detailed description of the primary and secondary trial outcomes and the methods for statistical comparison.Keywords
This publication has 16 references indexed in Scilit:
- Patient-Directed Education to Promote DeprescribingJAMA Internal Medicine, 2024
- What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medicationsTherapeutic Advances in Psychopharmacology, 2021
- Brief interventions targeting long‐term benzodiazepine and Z‐drug use in primary care: a systematic review and meta‐analysisAddiction, 2020
- The PRECIS-2 tool: designing trials that are fit for purposeBMJ, 2015
- Reduction of Inappropriate Benzodiazepine Prescriptions Among Older Adults Through Direct Patient EducationJAMA Internal Medicine, 2014
- The Development and Psychometric Evaluation of the Emotional Reactivity and Numbing ScaleJournal of Nervous & Mental Disease, 2007
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006
- The PHQ-9Journal of General Internal Medicine, 2001
- The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medicationPsychology & Health, 1999
- A 12-Item Short-Form Health SurveyMedical Care, 1996